Late-Stage CNS Drugs Key For Alkermes, But Early-Stage IL-2 Agonist Fascinates
Executive Summary
Immuno-oncology R&D based around an interleukin-2 agonist in early clinical studies has attracted attention to Alkermes, but the CNS disorders specialty company is also concentrating on a new mechanism-of-action antidepressant that is nearing the market, and a new antipsychotic.
You may also be interested in...
Alkermes’ Pops Lays Out Novel Drug Vision For Year Ahead
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.
FDA Refuse-To-File Letter For Alkermes Depression Drug Suggests A Lengthy Commercial Delay
CEO Richard Pops called FDA's letter for ALKS 5461 "surprising and troubling." Alkermes had been ramping up to launch the depression drug later this year, though some investors had remained skeptical.
Nektar/Bristol Deal May Shake Up Immuno-Oncology Landscape
The multibillion-dollar collaboration includes 20 studies, including two pivotal trials in renal cell carcinoma and non-small cell lung cancer that will start in the middle of the year.